Kinderarztpraxis Dr Kaiser - Dr. Marinesse
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
Kinderarztpraxis Dr Kaiser - Dr. Marinesse is conducting pediatric research focused on meningococcal infection, with studies designed to assess whether MenACYW conjugate vaccine can generate a strong and lasting immune response in young children. The work centers on immunogenicity and safety, helping determine how well vaccination strategies protect infants, toddlers, children, and adolescents against serious bacterial disease.
- Evaluating immune response to meningococcal ACYW vaccination in healthy infants and toddlers
- Studying booster vaccination to support long-term protection against meningococcal serogroups A, C, W, and Y
- Assessing antibody persistence and vaccine response over time in children and adolescents
These trials are helping clarify how well vaccines maintain protection across early childhood and beyond, with a practical focus on preventing invasive bacterial illness.
Virus Diseases
The site is also involved in research on viral respiratory disease, especially RSV in infants and toddlers. These studies aim to evaluate whether a vaccine can reduce the risk of serious lower respiratory tract illness while also measuring the body’s immune response and overall tolerability.
- Testing a vaccine approach for prevention of RSV lower respiratory tract disease
- Measuring immunogenicity and safety in young children
- Supporting efforts to improve protection against common childhood virus diseases
This line of research reflects a broader effort to strengthen early-life defense against respiratory infections, an important area of pediatric care in Hamburg and across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Sanofi Pasteur2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kinderarztpraxis Dr Kaiser - Dr. Marinesse
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of MenACYW Conjugate Vaccine Booster in Pediatric and Adolescent Populations with Prior Vaccination | Sanofi Pasteur | Phase III | Not Recruiting | Aug 2022 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid | 2 | Unknown | 2022-08-23 | 2024-03-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.